The global geothermal heat pumps market players are struggling to achieve a steady and noticeable position in the market through product improvement while the level of rivalry amongst them is extreme. The global geothermal heat pumps mar…
BMI View: Germany's large and expanding pharmaceutical market will continue to generate commercial
opportunities for drugmakers over the forecast period. While Germany's ongoing economic rebalancing
will continue to support robust domestic consumption indices, including in health sector segments,
healthcare spending will also be driven by population growth owing to net migration in the medium term.
Meanwhile, German economic resilience after the UK's EU referendum vote bodes well for the country's
healthcare and pharmaceuticals growth story. However, heightened economic and political risks will
remain a key concern for Germany, posing downside risks to our sector forecasts.
Headline Expenditure Projections
? Pharmaceuticals: EUR46.50bn (USD50.62bn) in 2015 to EUR46.98bn (USD51.68bn) in 2016; +1.0%
in local currency terms and 2.1% in US dollar terms. Forecast revised downwards in local currency
terms and upwards in US dollar terms from last quarter.
? Healthcare: EUR339.63bn (USD369.76bn) in 2015 to EUR350.32bn (USD385.35bn) in 2016; +3.2% in
local currency terms and +4.2% in US dollar terms. Forecast revised upwards from last quarter.